Christy Oswalt, MD
Endocrinology, Diabetes & Metabolism · Tupelo, MSNPI 1053474577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,688 of the $27,427 with a category attached, or 71.8%. 25 manufacturers reported payments, led by Lilly USA, LLC at 49.9% of the total.
Across 429 payments — averaging $63.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$14K
- Boehringer Ingelheim$10K
- Novo Nordisk$1K
- AbbVie$750
- Sanofi-aventis U.S. LLC$367
- Merck$319
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$19,68872%
- Travel & lodging$1,2084%
- Food & beverage$6,52224%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 119 | $13,692 |
| Boehringer Ingelheim | 55 | $9,768 |
| Novo Nordisk | 89 | $1,294 |
| AbbVie(2 entities) | 45 | $750 |
| Sanofi-aventis U.S. LLC | 25 | $367 |
| Merck | 22 | $319 |
| Amgen | 8 | $139 |
| IBSA Pharma Inc. | 7 | $124 |
| Sequel Med Tech, LLC | 5 | $98 |
| AstraZeneca | 7 | $96 |
| Insulet Corporation | 4 | $94 |
| Esperion Therapeutics, Inc. | 6 | $92 |
| Bayer | 5 | $83 |
| Shield Therapeutics Inc | 5 | $80 |
| Tandem Diabetes Care, Inc. | 6 | $80 |
| Johnson & Johnson | 5 | $72 |
| Medtronic(2 entities) | 4 | $69 |
| Novartis | 4 | $64 |
| Pfizer | 1 | $30 |
| Shire North American Group Inc | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$19,079
How this compares
$27,427 in reported general payments places this provider in the 75th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 365 | $387,031 |
| MounjaroTirzepatide | 338 | $372,677 |
| JardianceEmpagliflozin | 375 | $277,337 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 96 | $70,467 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $58,107 |
| TrulicityDulaglutide | 46 | $49,555 |
| FarxigaDapagliflozin Propanediol | 55 | $42,565 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $39,500 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $37,600 |
| WegovySemaglutide | 23 | $30,214 |
| SynthroidLevothyroxine Sodium | 345 | $26,111 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $24,610 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $23,268 |
| RybelsusSemaglutide | 13 | $22,710 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $19,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus, Fiasp, Novolog | $1,294 | $466,944450 claims |
| Lilly USA, LLCMounjaro, Trulicity | $13,692 | $422,232384 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi | $9,768 | $376,745500 claims |
| AstraZenecaFarxiga | $96 | $42,56555 claims |
| AbbVieSynthroid | $750 | $26,111345 claims |
| MerckJanuvia, Janumet Xr | $319 | $21,45430 claims |
| PfizerEliquis | $30 | $9,32917 claims |
| IBSA Pharma Inc.Tirosint | $124 | $2,65520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Tupelo
- Leonil GanlimTupelo$19K
- Mark ShepherdTupelo$17K
- Jayant DeyTupelo$1K
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Delali BlavoSouthaven$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.